Articles related to Hematology

Anaphylaxis to the mRNA COVID-19 vaccines is currently estimated to occur in 2.5 to 11.1 cases per million doses, largely in individuals with a history of allergy. In this JAMA “Research Letter”, the authors investigated acute allergic reaction incidence with more than 60,000 mRNA COVID-19 vaccine administrations at Mass General Brigham (MGB).

From MedPage Today comes this inspirational story about Christopher Veal, a medical student at UVM’s Larner College of Medicine who is calling on medical school leaders to change their culture and adjust their programs to screen for suicidal ideation and mental health early on in student life. Veal decided to speak up after a friend and fellow med student took his own life, as Veal once attempted.

There are more than 20,000 drugs approved for sale in the United States, and over the course of time, the sales of these drugs ebb and flow based on many factors. But some stay the course of time and reveal new indications or uses based on renewed clinical research. Here are five “old” drugs that are enjoying a renaissance right now, including thalidomide and its long, dark history.

Doctors, along with the rest of the nation, are drinking more during the pandemic. Five or more drinks a week is now standard fare for about 30% of Baby Boomer physicians, 26% of Generation X physicians, and 22% of Millennial doctors, up from the previous year by about 7%. But which specialties are drinking the most? Find out in this revealing report.

Just like how a great player will not necessarily make a great coach, not all physicians or healthcare providers are cut out to be health leaders. The smallest details are important, and the absolute best medical leaders can improve patient outcomes and staff morale while influencing positive change and inspiring others. Learn if you’ve got the chops for leadership by viewing these eight qualities of effectiveness.

In this Original Investigation from JAMA, the authors discuss the results of a randomized clinical trial that included 208 patients with high- and intermediate-risk first relapse of B-cell acute lymphoblastic leukemia (ALL). Did postreinduction treatment with blinatumomab compared with chemotherapy, followed by hematopoietic stem cell transplant, result in a statistically significant difference in disease-free survival?